Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 2018, 2941783

Visual Features in Alzheimer's Disease: From Basic Mechanisms to Clinical Overview


Visual Features in Alzheimer's Disease: From Basic Mechanisms to Clinical Overview

María Alejandra Cerquera-Jaramillo et al. Neural Plast.


Alzheimer's disease (AD) is the leading cause of dementia worldwide. It compromises patients' daily activities owing to progressive cognitive deterioration, which has elevated direct and indirect costs. Although AD has several risk factors, aging is considered the most important. Unfortunately, clinical diagnosis is usually performed at an advanced disease stage when dementia is established, making implementation of successful therapeutic interventions difficult. Current biomarkers tend to be expensive, insufficient, or invasive, raising the need for novel, improved tools aimed at early disease detection. AD is characterized by brain atrophy due to neuronal and synaptic loss, extracellular amyloid plaques composed of amyloid-beta peptide (Aβ), and neurofibrillary tangles of hyperphosphorylated tau protein. The visual system and central nervous system share many functional components. Thus, it is plausible that damage induced by Aβ, tau, and neuroinflammation may be observed in visual components such as the retina, even at an early disease stage. This underscores the importance of implementing ophthalmological examinations, less invasive and expensive than other biomarkers, as useful measures to assess disease progression and severity in individuals with or at risk of AD. Here, we review functional and morphological changes of the retina and visual pathway in AD from pathophysiological and clinical perspectives.


Figure 1
Figure 1
Pathophysiological events in the retina during Alzheimer's disease progression. Amyloid-beta (Aβ) induces microglia and astrocyte activation, synaptic dysfunction, and neurodegeneration. These interactions can be observed by noninvasive ophthalmological examinations in the retina at different stages of Alzheimer's disease (AD). Reduction in the peripapillary region and macular volume has been described in MCI and AD. AA: arachidonic acid; Aβ: amyloid-beta; ACh: acetylcholine; AD: Alzheimer's disease; MCI: mild cognitive impairment; NO: nitric oxide; OS: oxidative stress; PG: prostaglandins; RGC: retinal ganglion cells.

Similar articles

See all similar articles

Cited by 2 PubMed Central articles


    1. Scheltens P., Blennow K., Breteler M. M. B., et al. Alzheimer’s disease. The Lancet. 2016;388(10043):505–517. doi: 10.1016/S0140-6736(15)01124-1. - DOI - PubMed
    1. Ashraf G. M., Chibber S., Mohammad, et al. Recent updates on the association between Alzheimer’s disease and vascular dementia. Medicinal Chemistry. 2016;12(3):226–237. doi: 10.2174/1573406411666151030111820. - DOI - PubMed
    1. Prince M., Wimo A., Guerchet M., Ali G.-C., Wu Y.-T., Prina M. World Alzheimer Report 2015: The Global Impact of Dementia: an Analysis of Prevalence, Incidence, Cost and Trends. London: Alzheimer’s Disease International; 2015.
    1. Hickman R. A., Faustin A., Wisniewski T. Alzheimer disease and its growing epidemic: risk factors, biomarkers, and the urgent need for therapeutics. Neurologic Clinics. 2016;34(4):941–953. doi: 10.1016/j.ncl.2016.06.009. - DOI - PMC - PubMed
    1. Lane C. A., Hardy J., Schott J. M. Alzheimer’s disease. European Journal of Neurology. 2018;25(1):59–70. doi: 10.1111/ene.13439. - DOI - PubMed

MeSH terms